公开(公告)号：US12084436B2

公开(公告)日：2024-09-10

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Hideyuki Sugiyama ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Osamu Kubo ,  Akinori Toita ,  Takuto Kojima ,  Fumiaki Kikuchi ,  Minoru Sasaki ,  Misaki Homma ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Shiinobu Sasaki ,  Ayumu Sato ,  Hirotaka Kamitani ,  Yasutomi Asano ,  Hironori Kokubo ,  Masato Yoshikawa

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US09428470B2

公开(公告)日：2016-08-30

申请号：US14619464

申请日：2015-02-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zenichi Ikeda ,  Minoru Sasaki ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Yoichi Nishikawa

IPC: C07D261/04 ,  C07D413/10

CPC classification number: C07D261/04 ,  C07D413/10

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

Abstract translation: 提供具有肠肽酶抑制作用的稠合杂环化合物和该化合物作为治疗或预防肥胖症，糖尿病等的药物的用途。 具体地，提供由下式（I）表示的化合物：其中每个符号如本文所定义，或其盐，并且使用该化合物作为治疗或预防肥胖，糖尿病等的药物。

公开(公告)号：US09969705B2

公开(公告)日：2018-05-15

申请号：US15117538

申请日：2015-02-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru Sasaki ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Zenichi Ikeda ,  Yoichi Nishikawa

IPC: C07D307/81

CPC classification number: C07D307/81

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US09371320B2

公开(公告)日：2016-06-21

申请号：US14404126

申请日：2013-05-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi Nara ,  Masaki Daini ,  Akira Kaieda ,  Toshihiro Imaeda ,  Fumiaki Kikuchi

IPC: C07D401/14 ,  A61K31/437 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有优异的JAK抑制作用的化合物，其可用作预防或治疗自身免疫性疾病（类风湿性关节炎，牛皮癣，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮， 等），癌症（白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等，或其盐。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20150225354A1

公开(公告)日：2015-08-13

申请号：US14619464

申请日：2015-02-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zenichi Ikeda ,  Minoru Sasaki ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Yoichi Nishikawa

IPC: C07D261/04 ,  C07D413/10

CPC classification number: C07D261/04 ,  C07D413/10

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

Abstract translation: 提供具有肠肽酶抑制作用的稠合杂环化合物和该化合物作为治疗或预防肥胖症，糖尿病等的药物的用途。 具体地，提供由下式（I）表示的化合物：其中每个符号如本文所定义，或其盐，并且使用该化合物作为治疗或预防肥胖，糖尿病等的药物。

公开(公告)号：US11459325B2

公开(公告)日：2022-10-04

申请号：US16961476

申请日：2019-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta Tanaka ,  Tomohiro Ohashi ,  Zenichi Ikeda ,  Yuta Tanaka ,  Florian Pünner ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Nao Morishita ,  Takahito Kasahara ,  Masaki Seto ,  Minoru Nakamura ,  Kazuaki Takami ,  Masataka Murakami ,  Masaki Daini ,  Satoshi Mikami ,  Minoru Sasaki

IPC: C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61P25/28

Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10435399B2

公开(公告)日：2019-10-08

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Osamu Kubo ,  Fumiaki Kikuchi ,  Takeshi Yasui ,  Keiko Kakegawa ,  Zenichi Ikeda ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Akinori Toita ,  Takuto Kojima ,  Yasutomi Asano ,  Ayumu Sato ,  Hironobu Maezaki ,  Shinobu Sasaki ,  Hironori Kokubo ,  Misaki Homma ,  Minoru Sasaki ,  Yasuhiro Imaeda

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D487/04 ,  A61P25/28 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10023544B2

公开(公告)日：2018-07-17

申请号：US15117539

申请日：2015-02-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zenichi Ikeda ,  Minoru Sasaki ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Yoichi Nishikawa

IPC: C07D261/04 ,  C07D413/10

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

公开(公告)号：US09975903B2

公开(公告)日：2018-05-22

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru Sasaki ,  Fumiaki Kikuchi ,  Zenichi Ikeda ,  Keiko Kakegawa ,  Yoichi Nishikawa ,  Shigekazu Sasaki ,  Koichiro Fukuda ,  Kazuaki Takami ,  Yoshihiro Banno ,  Masahiro Kamaura

IPC: C07D493/04 ,  C07D495/04 ,  C07D321/00 ,  C07D405/06 ,  C07D321/12 ,  C07D413/06 ,  C07D323/00 ,  C07D491/044 ,  C07D313/00 ,  C07D313/20

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].

公开(公告)号：US09346776B2

公开(公告)日：2016-05-24

申请号：US14619489

申请日：2015-02-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zenichi Ikeda ,  Minoru Sasaki ,  Keiko Kakegawa ,  Fumiaki Kikuchi ,  Yoichi Nishikawa

IPC: C07D307/81

CPC classification number: C07D307/81

Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

Abstract translation: 提供具有肠肽酶抑制作用的稠合杂环化合物和该化合物作为治疗或预防肥胖症，糖尿病等的药物的用途。 具体地，提供由下式（I）表示的化合物：其中每个符号如本文所定义，或其盐，并且使用该化合物作为治疗或预防肥胖，糖尿病等的药物。